Resumen de acción ROVI
Laboratorios Farmacéuticos Rovi, S.A. se dedica a la investigación, desarrollo, fabricación y comercialización de productos farmacéuticos en España y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en ROVI a partir de nuestros controles de riesgos.
Competidores de Laboratorios Farmaceuticos Rovi, S.A.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €85.75 |
| 52 Week High | €86.95 |
| 52 Week Low | €37.96 |
| Beta | 0.48 |
| 1 Month Change | 5.02% |
| 3 Month Change | 22.24% |
| 1 Year Change | 102.43% |
| 3 Year Change | 62.41% |
| 5 Year Change | 363.51% |
| Change since IPO | 757.50% |
Noticias y actualizaciones recientes
Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price
May 08
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Apr 17Recent updates
Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price
May 08These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Apr 17Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?
Feb 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Dec 21Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?
Nov 03Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Aug 26Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jul 14Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
May 26Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?
May 05Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate
Apr 11Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
Feb 22An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued
Dec 10These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Nov 04Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?
Sep 15Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Aug 28Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Jun 15I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease
Feb 13Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Jan 02A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Dec 12Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Nov 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Sep 24Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Jun 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Apr 06Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%
Mar 15If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late
Feb 16
Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?
Jan 26These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Jan 04Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years
Dec 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?
Nov 26Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jul 06Rentabilidad de los accionistas
| ROVI | ES Pharmaceuticals | Mercado ES | |
|---|---|---|---|
| 7D | 5.2% | 4.7% | 2.3% |
| 1Y | 102.4% | 12.2% | 19.6% |
Rentabilidad vs. Industria: ROVI superó al sector Spanish Pharmaceuticals , que obtuvo un rendimiento del 42.2% el año pasado.
Rentabilidad vs. Mercado: ROVI superó al mercado Spanish, que obtuvo un rendimiento del 14.8% el año pasado.
Volatilidad de los precios
| ROVI volatility | |
|---|---|
| ROVI Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in ES Market | 7.2% |
| 10% least volatile stocks in ES Market | 1.1% |
Precio estable de las acciones: ROVI no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ROVI (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1946 | 1,925 | Juan Lopez-Belmonte Encina | www.rovi.es |
Laboratorios Farmacéuticos Rovi, S.A. se dedica a la investigación, desarrollo, fabricación y comercialización de productos farmacéuticos en España y a nivel internacional. La empresa ofrece productos para cardiología, osteoarticulares/salud femenina, anestesia/dolor, agentes de contraste para diagnóstico por imagen, sistema nervioso central, urología, endocrinología, respiratorio y atención primaria. Sus principales productos son Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler y Volutsa; y productos hospitalarios, como Iomeron e Iopamiro, Multihance e Y Prohance, Sonovue, Empowercta+, Empowermr y CT Express, Fibrilin y Sodium Heparin Rovi.
Resumen de fundamentos de Laboratorios Farmaceuticos Rovi, S.A.
| Estadísticas fundamentales de ROVI | |
|---|---|
| Capitalización bursátil | €4.44b |
| Beneficios(TTM) | €137.84m |
| Ingresos (TTM) | €779.05m |
32.2x
Ratio precio-beneficio (PE)5.7x
Ratio precio-ventas (PS)¿Está ROVI sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ROVI | |
|---|---|
| Ingresos | €779.05m |
| Coste de los ingresos | €327.12m |
| Beneficio bruto | €451.93m |
| Otros gastos | €314.10m |
| Beneficios | €137.84m |
Últimos beneficios comunicados
Mar 31, 2024
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 2.66 |
| Margen bruto | 58.01% |
| Margen de beneficio neto | 17.69% |
| Ratio deuda/patrimonio | 15.6% |
¿Cómo se ha desempeñado ROVI a largo plazo?
Ver rendimiento histórico y comparativa